PMPRB issues a Notice of Hearing for allegations of excessive pricing of PROCYSBI
The Board will hold a public hearing (on a date to be determined no later than February 27, 2019) to determine whether Horizon Therapeutics Canada is selling or has sold PROCYSBI (cysteamine bitartrate) in any market in Canada at a price that, in the Board's opinion, is or was excessive; and if so, what order, if any, should be made to remedy the excessive pricing.
News Release; Notice of Hearing; Statement of Allegations of Board Staff
Under reserve: Appeal from judicial review quashing PMPRB decision on jurisdiction over DIFFERIN
On January 17, 2019, the Federal Court of Appeal heard the Attorney General of Canada’s appeal from a judicial review that quashed a Board decision that it has jurisdiction over Galderma’s DIFFERIN (0.1% adapalene). Our report on the Federal Court decision, 2017 FC 1023, is found here. Innovative Medicines Canada intervened in the appeal. The Federal Court of Appeal reserved judgment.
Related Publications & Articles
-
Health Canada proposes amendments to the Food and Drug Regulations and Medical Devices Regulations to modernize framework for therapeutic product recalls
On April 15, 2023, Health Canada proposed amendments to the Food and Drug Regulations and the Medical Devices Regulations (together, the “Proposed Amendments”).Read More -
Proposed legislation for patent term adjustment, and the interplay with CSPs
Bill C-47 is an omnibus bill that includes proposed amendments to the Patent Act to introduce patent term adjustment to compensate the patentee for Patent Office delays in granting a patent.Read More -
Health Canada publishes revised Guidance Document: Certificates of Supplementary Protection (CSP)
On May 12, 2023, Health Canada announced the fifth version of the Guidance Document: Certificates of Supplementary Protection. The changes are desRead More